E
Elisa de Stanchina
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 268
Citations - 26387
Elisa de Stanchina is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 65, co-authored 201 publications receiving 21076 citations. Previous affiliations of Elisa de Stanchina include Kettering University & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
Kamini Singh,Jianan Lin,Nicolas Lecomte,Prathibha Mohan,Askan Gokce,Viraj Sanghvi,Viraj Sanghvi,Man Jiang,Olivera Grbovic-Huezo,Antonija Burčul,Stefan G. Stark,Stefan G. Stark,Paul B. Romesser,Qing Chang,Jerry P. Melchor,Rachel K. Beyer,Mark Duggan,Yoshiyuki Fukase,Guangli Yang,Ouathek Ouerfelli,Agnes Viale,Elisa de Stanchina,Andrew W. Stamford,Peter T. Meinke,Gunnar Rätsch,Gunnar Rätsch,Steven D. Leach,Zhengqing Ouyang,Hans-Guido Wendel +28 more
TL;DR: The authors showed that the eIF4A RNA helicase is required for translation of key KRAS signaling molecules and showed that pharmacological inhibition of eif4A has single-agent activity against murine and human PDAC models at safe dose levels.
Journal ArticleDOI
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
Ninghui Mao,Zeda Zhang,Young Sun Lee,Danielle Choi,Aura Agudelo Rivera,Dan Li,Cindy Lee,Samuel Haywood,Xiaoping Chen,Qing Chang,Guotai Xu,Hsuan-An Chen,Elisa de Stanchina,Charles L. Sawyers,Neal Rosen,Andrew C. Hsieh,Yu Chen,Brett S. Carver +17 more
TL;DR: In this paper, the authors used a panel pre-clinical models to reveal that PI3K isoform dependency is not governed by loss of PTEN and is impacted by feedback inhibition and concurrent PIK3CA/PIK3CB alterations.
Journal ArticleDOI
gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.
Ellinor I.B. Peerschke,Kenneth Stier,Xiaoyu Li,Xiaoyu Li,Evelyn Kandov,Elisa de Stanchina,Qing Chang,Xiong Yuquan,Katia Manova-Todorova,Ning Fan,Afsar Barlas,Berhane Ghebrehiwet,Prasad S. Adusumilli +12 more
TL;DR: In vitro and in vivo experiments identify gC1qR as a potential new therapeutic target against mesothelioma with both antiproliferative and antiangiogenic properties.
Journal ArticleDOI
Maitake Beta-Glucan Enhances Umbilical Cord Blood Stem Cell Transplantation in the NOD/SCID Mouse:
Hong Lin,Elisa de Stanchina,Xi Kathy Zhou,Yuhong She,Danthanh Hoang,Sandy Cheung,Barrie R. Cassileth,Susanna Cunningham-Rundles +7 more
TL;DR: The studies suggest that MBG promotes hematopoiesis through effects on CD34+ progenitor cell expansion ex vivo and when given to the transplant recipient could enhanceCD34+ precursor cell homing and support engraftment.
Journal ArticleDOI
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
Takuo Hayashi,Igor Odintsov,Roger S. Smith,Kota Ishizawa,Allan J.W. Liu,Allan J.W. Liu,Lukas Delasos,Christopher Kurzatkowski,Huichun Tai,Eric Gladstone,Morana Vojnic,Shinji Kohsaka,Ken Suzawa,Zebing Liu,Siddharth Kunte,Marissa Mattar,Inna Khodos,Monika A. Davare,Alexander Drilon,Emily H. Cheng,Elisa de Stanchina,Marc Ladanyi,Romel Somwar +22 more
TL;DR: Establishment of four patient-derived models of RET fusion-positive lung adenocarcinomas with three different RET fusions shows that MYC expression is regulated by RET, opening up potentially new therapeutic avenues for the combinatorial targetin of RET fused lung cancers.